Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Norwegian oil giant Statoil ASA ( STO - Analyst Report ) along with its partners has decided to advance on the development of Aasta Hansteen –– a field in the Norwegian Sea. This capital intensive project is estimated at about NOK 32 billion ($5.8 billion).
The decision for development, which was anticipated by the end of 2012, was pushed over to 2013 as it involved the construction of a new 480-kilometer (298 miles) gas export pipeline from the field to the Nyhamna processing plant near Molde. This requirement made it difficult for the project partners –– Statoil, OMV and ConocoPhillips ( COP - Analyst Report ) –– to come to a decision.
The participants are now preparing to submit their plan for the development and operation (PDO) of the field to the Petroleum & Energy Ministry early this year so that they get their consent in the spring session of the parliament.
The uncertainty with respect to the progress of the Aasta Hansteen development was partly due to the arguments regarding cost sharing of development of a new pipeline, Polarpipe, which cost about NOK 11.1 billion.
The partners of Aasta Hansteen have engaged 10 other Norwegian Sea players in the pipeline investor group to talk about cost sharing of the estimated NOK 11.1 billion for the Polarpipe link. Some players have worked up a plan that is suitable to both Aasta Hansteen partners as well as other companies that might want to use the route in the future.
Statoil, the operator of the field, is expected to hand over the PDO for Aasta Hansteen and for the Polarpipe to the Petroleum & Energy Minister early next week. The development of this field will open up avenues for gas pipeline connection to the Barents Sea. This will offer an export solution for future field developments in the remote Arctic region.
Lying in a water depth of 1300 meters –– Aasta Hansteen –– will be developed by Statoil using the world’s largest spar platform. The field is expected to start production in late 2016.
Statoil holds a Zacks #5 Rank (short-term Strong Sell rating). For the longer term, we maintain our Underperform recommendation.
Read the full Analyst Report on STO
Read the full Analyst Report on COP